Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2…
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily…